Very proud of Pedro C Barata, MD MSc FACP who worked hard with Alex Chehrazi-Raffle, MD & the AVEO Oncology team (@oncdoc67 Kim Allman Marge Karas) to resurface data from the RDT of #tivozanib pertaining to non-clear cell #kidneycancer . See his recent paper in The Oncologist here! vaishamu Brian Shuch, MD…

Brian Rini, MD and Tom Powles have launched a new website, Uromigos.org, featuring podcasts, videos, Uromigos Live annual meeting material and much more! Visit soon for #GU23 content.

Sumanta K. Pal, MD, FASCO Shilpa Gupta Petros Grivas Neeraj Agarwal, MD, FASCO Enrique Grande Toni Choueiri, MD

I would definitely recommend The Fellow On Call podcast to anyone interested in Hematology and oncology. This is the best podcast I’ve listened to for helping teach the fundamentals learned during fellowship

Just find out that JAGarciaMD is the new chair of the U.S. FDA ODAC… Uau! Fantastic news!! so well deserved…. proud to call him a mentor and friend… University Hospitals Daniel E Spratt Dr. Theodoros Teknos Jason Brown Prateek Mendiratta Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Brian Rini, MD

🚨OUT NOW: #FreeAccess
☑️Comparison of Papillary RCC Type 1 & 2
☑️Roundtable: Tivozanib+ Nivolumab Strategies
☑️Engineered T-Cell Therapy
☑️ASCO'22: Highlights & Top Abstracts.

Check out 👉 kidney-cancer-journal.com

#KidneyCancer #RCC

Cristiane D Bergerot ASCO Paulo G Bergerot Sumanta K. Pal, MD, FASCO Shilpa Gupta Neeraj Agarwal, MD, FASCO Petros Grivas #FlorezLab #LatinasInMedicine #LatinosInOncology Thanks for highlighting Cristiane D Bergerot! Great effort from AVEO Oncology to retrieve data from non cc histologies and report this. Also great mentorship from Sumanta K. Pal, MD, FASCO !
Kim Allman ASCO

📍 Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial ASCO #ASCO22 Pedro C Barata, MD MSc FACP

meetings.asco.org/abstracts-pres…

There have been many changes to kidney cancer treatment over the years, but one oncology nurse is consistently 'ahead of the curve' when it comes to patient education. Kidney Cancer ow.ly/MtkE50J3QVi

Proud to present our poster at #ONScongress on the value of the oncology APP voice in medical advisory boards and its ability to lead to the generation of critical educational content for nurses and APPs with Marge Karas

Real-world treatment trends in metastatic castration-resistant #ProstateCancer . Pedro C Barata, MD MSc FACP Tulane University joins Alicia Morgans, MD, MPH Dana-Farber to discuss patient treatment data in the metastatic prostate cancer setting. #WatchNow on UroToday > bit.ly/3wQp1ET ASCO #GU22

Immunotherapy Could Still Play a Role After Progression in Patients With RCC Moshe Ornstein MD Cleveland Clinic #kcsm ow.ly/u7RL50I85hG

Yes she is! #beastmode Ashlynn Shade

Ashlynn Shade is nice!

$AVEO Oncology announces data from the DEDUCTIVE study of FOTIVDA® (tivozanib) combined with IMFINZI® (durvalumab) in previously untreated metastatic hepatocellular carcinoma (HCC). Data were presented at 2022 ASCO GI Cancer Symposium. @RenukaIyer
bit.ly/3rAjbDx #GI22

Our beloved Laura Wood, RN, KidneyCAN Cleveland Clinic MD tragically lost her daughter, Danielle to a vehicle accident when walking to @MC2STEMHigh where she taught chemistry.

Please support Danielle Chronister Memorial Scholarship Fund 🙏👇

gofund.me/ee8c6e78

Everything you wanted to know about PD-1/VEGF combination toxicity management in RCC but were afraid to ask. Elizabeth Plimack MD anchor.fm/the-uromigos/e…

Some clinically useful data regarding LFT abnormalities from axi/pembro and outcomes of rechallenge, mgmt strategies etc.

authors.elsevier.com/a/1dMW59Cfv-qB…

Conundrums in 1L Urothelial Ca: is more always better? Honored to discuss oral abstracts highlighting important data from novel trials #BladderCancer by Sumanta K. Pal, MD, FASCO Arjun Balar MD Peter O’ Donnell ASCO #ASCO21 Cleveland Clinic MD

Case: Adenocarcinoma of Prostate Gleason 5+5.
Written by Pedro C. Barata MD
Pedro C Barata, MD MSc FACP Tulane Urology #pcsm

Add your input to the case discussion: spkl.io/60124MeDo